Treating women diagnosed with one type of early-stage breast cancer with the monoclonal antibody trastuzumab after surgery reduces the risk of the cancer returning, reports a research team led by University of Saskatchewan ...
Jan 31, 2022
0
54
A moderate amount of a peptide-enhanced, biological cancer drug goes a long way in treating breast cancers that metastasize to the bone.
Jan 24, 2022
0
76
Thomas Hatschek, associate professor at the department of Oncology-Pathology, together with colleagues, has recently published an article in JAMA Oncology showing that a new treatment for breast cancer with an antibody linked ...
Aug 18, 2021
0
337
(Medical Xpress)—Bioengineering researchers at University of California, Santa Barbara have found that changing the shape of chemotherapy drug nanoparticles from spherical to rod-shaped made them up to 10,000 times more ...
Feb 27, 2013
0
0
For patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer previously treated with trastuzumab and a taxane, the risk of progression or death from any cause is lower with trastuzumab ...
Mar 24, 2022
0
6
The NRG Oncology clinical trial NRG-RTOG 1010, studying the addition of the drug trastuzumab to chemoradiation and surgery, did not reach its primary goal of improving disease-free survival (DFS) rates for patients with HER2 ...
Jan 21, 2022
0
15
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results ...
Jun 29, 2020
0
2
Anthracyclines remain a cornerstone of breast cancer therapy in combination with new-generation targeted drugs such as trastuzumab. Both types of drugs are major culprits in chemotherapy-induced heart disease. A recent study ...
Dec 23, 2019
0
2
The World Health Organization (WHO) announced Wednesday that it had for the first time approved a "biosimilar" medicine—one derived from living sources rather than chemicals—to make breast cancer treatment affordable ...
Dec 18, 2019
0
17
The trastuzumab biosimilar HLX02 achieved similar overall response rate to reference trastuzumab in women with human epidermal growth factor receptor 2-positive (HER2+) recurrent or previously untreated metastatic breast ...
Nov 22, 2019
0
2
